Mycobacterium tuberculosis—thioredoxin reductase inhibitor as an antitubercular agent

A compound which is selected from the group consisting of:

• 6-methoxy-2-methyl-N-(4-((4-(pyridin-4-ylamino)phenyl)sulfonyl)phenyl)quinolin-4-amine (2):
• N-(4-((4-aminophenyl)sulfonyl)phenyl)-6-methoxy-2-methylquinolin-4-amine (9):
• N-(4-((4-((6-methoxy-2-methylquinolin-4-yl)amino)phenyl)sulfonyl)phenyl)acetamide (10):
• 6-methoxy-2-methyl-N-(4-((4-(pyrimidin-4-yl-amino)phenyl)sulfonyl)phenyl)quinolin-4-amine (24):
• N-(4-((4-((3-(tert-butyl)-1H-pyrazol-5-yl)amino)phenyl)sulfonyl)phenyl)-6methoxy-2-methylquinolin-4-amine (25):
• 6-methoxy-N-(4-((4-((4-methoxyphenyl)amino)phenyl)sulfonyl)phenyl)-2-methylquinolin-4-amine (26):
• methyl-4-((4-((4-((6-methoxy-2-methylquinolin-4-yl)amino)phenyl)sulfonyl)phenyl)amino) benzoate (27):
• (4-((6-methoxy-2-methylquinolin-4-yl)amino)phenyl)(4-(pyridin-4-yl-amino) phenyl)methanone (45):
• 6-methoxy-2-methyl-N-(4-(4-(pyridin-4-ylamino)benzyl)phenyl)quinolin-4-amine (63):
• 6-methoxy-2-methyl-N-(4-(4-(pyrimidin-4-ylamino)benzyl)phenyl)quinolin-4-amine (68):
• and
• physiologically acceptable salts thereof.